News · 26 weeks67+700%
2026-03-012026-08-23
Mix3290d
- Insider18(56%)
- SEC Filings10(31%)
- Earnings2(6%)
- Analyst1(3%)
- Other1(3%)
Latest news
25 items- INSIDERChief Financial Officer Hohenleitner Susan sold $6,009 worth of shares (1,558 units at $3.86), decreasing direct ownership by 0.68% to 227,520 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Reilly Joseph James sold $15,358 worth of shares (3,982 units at $3.86), decreasing direct ownership by 3% to 145,854 units (SEC Form 4) (for tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDEROfficer Bishop John E sold $76,174 worth of shares (19,750 units at $3.86), decreasing direct ownership by 6% to 317,095 units (SEC Form 4) to cover taxes4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Human Resources Officer Brady James Parker sold $58,378 worth of shares (15,136 units at $3.86), decreasing direct ownership by 6% to 245,930 units (SEC Form 4) (tax withholding)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Commercial Officer Foster Eric Duane sold $33,023 worth of shares (8,562 units at $3.86), decreasing direct ownership by 2% to 409,410 units (SEC Form 4) to cover withholding tax4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Business Officer Kelliher Mike sold $29,922 worth of shares (7,758 units at $3.86), decreasing direct ownership by 2% to 349,660 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERChief Patient Officer Williams Laura A sold $41,419 worth of shares (10,739 units at $3.86), decreasing direct ownership by 3% to 367,456 units (SEC Form 4) (tax liability)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERPresident & CEO Raab Michael sold $225,914 worth of shares (58,574 units at $3.86), decreasing direct ownership by 3% to 1,619,792 units (SEC Form 4) (withholding obligation)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 144 filed by Ardelyx Inc.144 - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form 8-K filed by Ardelyx Inc.8-K - ARDELYX, INC. (0001437402) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Ardelyx Inc.SCHEDULE 13G/A - ARDELYX, INC. (0001437402) (Subject)
- SECSEC Form S-8 filed by Ardelyx Inc.S-8 - ARDELYX, INC. (0001437402) (Filer)
- SECSEC Form 10-Q filed by Ardelyx Inc.10-Q - ARDELYX, INC. (0001437402) (Filer)
- SECArdelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARDELYX, INC. (0001437402) (Filer)
- PRArdelyx Reports Second Quarter 2026 Financial Results and Provides Business UpdateQ2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 million Strong financial position with $281.8 million in cash, cash equivalents and investments as of June 30, 2026 Revising FY 2026 and long-term guidance Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (NASDAQ:ARDX), ("Ardelyx" or the "Company") a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs,
- PRArdelyx to Report Second Quarter 2026 Financial Results on August 6, 2026WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX) ("Ardelyx" or the "Company"), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2026. Webcast InformationA live webcast of the conference call and accompanying slides will be available in the "Events and Presentations" section under "News and Events" within the Investors section of the Compan
- INSIDERPresident & CEO Raab Michael exercised 20,834 shares at a strike of $0.99 and sold $210,923 worth of shares (41,668 units at $5.06) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,678,366 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- SECArdelyx Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ARDELYX, INC. (0001437402) (Filer)
- INSIDERChief Patient Officer Williams Laura A exercised 31,000 shares at a strike of $0.99 and sold $490,487 worth of shares (81,898 units at $5.99) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 378,195 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Parsey Merdad was granted 26,455 shares, increasing direct ownership by 46% to 83,746 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Rodgers Richard J was granted 26,455 shares, increasing direct ownership by 6% to 439,998 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Mott David M was granted 46,737 shares, increasing direct ownership by 1% to 3,349,655 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Cadoret-Manier Onaiza was granted 26,455 shares, increasing direct ownership by 17% to 178,156 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
- INSIDERDirector Bhanji Muna was granted 26,455 shares, increasing direct ownership by 19% to 163,808 units (SEC Form 4)4 - ARDELYX, INC. (0001437402) (Issuer)
ARDX FAQ
7 questionsWhat does Ardelyx Inc. do?
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of...Where does ARDX stock trade?
Ardelyx Inc. (ARDX) is listed on NASDAQ.What sector and industry is ARDX in?
Ardelyx Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ardelyx Inc. go public?
Ardelyx Inc. (ARDX) completed its IPO in 2014.What are analysts saying about ARDX?
Ardelyx Inc. has had 8 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1600.00 price target on 2026-06-16. Recent price targets range from $550.00 to $1600.00.What companies are similar to ARDX?
Notable peers in the same industry include KDNY (Chinook Therapeutics Inc.), AKBA (Akebia Therapeutics Inc.), ZSAN (Zosano Pharma Corporation). Compare ARDX side-by-side with any of them on Quantisnow.How can I track ARDX on Quantisnow?
Quantisnow aggregates Ardelyx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARDX to receive live email and push alerts on every new disclosure.